We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients

By LabMedica International staff writers
Posted on 07 Apr 2025

Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. More...

However, over half of non-Hodgkin lymphoma (NHL) patients who fail to respond to conventional treatments also experience relapse or disease progression within six months after undergoing CAR T therapy. In response, a new tool using machine learning has been developed to predict how well an NHL patient might respond to CAR T-cell therapy prior to starting the treatment.

Called InflaMix (Inflammation Mixture Model), this innovative tool was developed by researchers at City of Hope (Duarte, CA, USA) to evaluate inflammation, which is considered a potential cause of CAR T failure, by testing for various blood biomarkers in 149 patients with NHL. Using machine learning, a form of artificial intelligence that analyzes data through algorithms to identify patterns and draw conclusions, the model was able to identify an inflammatory biomarker through a set of blood tests that are not typically used in standard clinical practice. By examining the inflammatory signature identified by InflaMix, the researchers found a significant association with an increased risk of CAR T treatment failure, including a higher risk of death or relapse. Notably, InflaMix is an unsupervised model, meaning it was trained without prior knowledge of clinical outcomes.

The research team noted that the machine learning model is highly adaptable, showing good performance even when using just six commonly available blood tests—tests that are typically evaluated for lymphoma patients—to assess InflaMix's functionality with less data. This is an important feature because it suggests that the test could be accessible to a broad range of lymphoma patients. To validate their initial findings, the researchers studied three independent cohorts, comprising 688 NHL patients with diverse clinical characteristics and disease subtypes who had received different CAR T products. Moving forward, the team plans to explore whether the inflammation identified by InflaMix directly impacts CAR T-cell function and to investigate the underlying sources of this inflammation.

“These studies demonstrate that by using machine learning and blood tests, we could develop a highly reliable tool that can help predict who will respond well to CAR T cell therapy,” said Marcel van den Brink, M.D., Ph.D., president of City of Hope Los Angeles and City of Hope National Medical Center, and a senior author of the paper published in Nature Medicine. “InflaMix could be used to reliably identify patients who are about to be treated with CAR T and are at high risk for the treatment not working. By identifying these patients, doctors may be able to design new clinical trials that can boost the effectiveness of CAR T with additional treatment strategies.”

Related Links:
City of Hope


New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS
New
PSA Test
Humasis PSA Card
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.